0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

BELLADONNA DRUGS IN CHOLINERGIC POISONING DURING TREATMENT OF MYASTHENIA GRAVIS

Robert S. Schwab, M.D.
JAMA. 1954;155(16):1445-1446. doi:10.1001/jama.1954.03690340067024.
Text Size: A A A
Published online

ABSTRACT

To the Editor.  —Since the introduction of neostigmine in 1934 by Mary Walker in the treatment of myasthenia gravis, various other anticholinesterase (cholinergic) drugs have been used in the treatment of this disease with varying success. Some of these, such as diisopropyl fluorophosphate (DFP), tetraethyl pyrophosphate (TEP), and octamethyl pyrophosphoramide (OMPA), produced long depression of the serum cholinesterase, depression lasting for from several days to several weeks. The most successful for treatment of myasthenia was octamethyl pyrophosphoramide, but this drug is no longer available because of the tremendous difficulties and dangers in its manufacture. With all of these drugs, as well as with neostigmine, the side-effects of intense stimulation of the gastrointestinal tract made it difficult to obtain a good therapeutic result in some patients unless belladonna derivatives were given with each dose of the anticholinesterase compound. When this was done, the gastrointestinal effects disappeared, but at the same time

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

* * SCHEDULED MAINTENANCE * *

Our websites may be periodically unavailable between midnight and 04:00 ET Thursday, July 10th, for regularly scheduled maintenance.

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();